- Home
- BPMC vs AXSM Comparison
BPMC vs AXSM Comparison
Compare BPMC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- AXSM
- Stock Information
- Founded
- BPMC 2008
- AXSM 2012
- Country
- BPMC United States
- AXSM United States
- Employees
- BPMC N/A
- AXSM N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- BPMC Health Care
- AXSM Health Care
- Exchange
- BPMC Nasdaq
- AXSM Nasdaq
- Market Cap
- BPMC 5.8B
- AXSM 5.1B
- IPO Year
- BPMC 2015
- AXSM 2015
- Fundamental
- Price
- BPMC $128.35
- AXSM $105.44
- Analyst Decision
- BPMC Buy
- AXSM Strong Buy
- Analyst Count
- BPMC 20
- AXSM 17
- Target Price
- BPMC $127.82
- AXSM $171.65
- AVG Volume (30 Days)
- BPMC 3.6M
- AXSM 649.3K
- Earning Date
- BPMC 07-31-2025
- AXSM 08-04-2025
- Dividend Yield
- BPMC N/A
- AXSM N/A
- EPS Growth
- BPMC N/A
- AXSM N/A
- EPS
- BPMC N/A
- AXSM N/A
- Revenue
- BPMC $562,121,000.00
- AXSM $432,157,000.00
- Revenue This Year
- BPMC $44.46
- AXSM $62.84
- Revenue Next Year
- BPMC $32.78
- AXSM $60.02
- P/E Ratio
- BPMC N/A
- AXSM N/A
- Revenue Growth
- BPMC 99.19
- AXSM 72.16
- 52 Week Low
- BPMC $73.04
- AXSM $72.21
- 52 Week High
- BPMC $128.52
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- BPMC 74.59
- AXSM 47.99
- Support Level
- BPMC $128.06
- AXSM $102.26
- Resistance Level
- BPMC $128.52
- AXSM $106.35
- Average True Range (ATR)
- BPMC 0.28
- AXSM 3.09
- MACD
- BPMC -1.18
- AXSM 0.15
- Stochastic Oscillator
- BPMC 74.44
- AXSM 66.44
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.